Management of painful symptoms with duloxetine: A review of the efficacy in pre-clinical and clinical studies

Current Drug Therapy

Volumn 6, Issue 2, 2011, Pages 121-136

  Robinson, Michael J ^a   Ahl, Jonna ^b   Meyers, Adam L ^b   McCarberg, Bill H ^c,d   Iyengar, Smriti ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Depression; Diabetic neuropathic pain; Duloxetine; Fibromyalgia; Pain

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DULOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO;

ACUTE NOCICEPTIVE PAIN; ANALGESIA; ARTICLE; BACKACHE; CHRONIC PAIN; CLINICAL RESEARCH; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HUMAN; INFLAMMATORY PAIN; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NEUROPATHIC PAIN; NONHUMAN; PAIN; PERSISTENT PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHOULDER PAIN; VISUAL ANALOG SCALE;

EID: 79960027669     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488511795304903     Document Type: Article

References (94)

1. Merskey H, Bogduk N, Eds. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain Terms, Second Ed. Seattle, WA: IASP Press 1994; 209-14.
2. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001; 2: 83-91.
3. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain 2002; 100: 1-6.
4. th ed. Elsevier Limited 2005; 125-42.
5. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
6. Jasmin L, Tien D, Janni G, Ohara PT. Is noradrenalin a significant factor in the analgesic effect of antidepressants? Pain 2003; 106(1-2): 3-8.
7. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 2006; 80(2): 53-83.
8. Carroll I, Mackey S, Gaeta R. The role of adrenergic receptors and pain: The good, the bad, and the unknown. Semin Anesthesia Periop Med Pain 2007; 26: 17-21.
9. Brightwell JJ, Taylor BK. Noradrenergic neurons in the locus coeruleus contribute to neuropathic pain. Neuroscience 2009; 160: 174-85.
10. Goettl VM, Huang Y, Hackshaw KV, Stephens RL Jr. Reduced basal release of serotonin from the ventrobasal thalamus of the rat model of neuropathic pain. Pain 2002; 99(1): 359-66.
11. Hains BC, Everhart AW, Fullwood SD, Hulsebosch CE. Changes in serotonin, serotonin transport expression, and serotonin denervation supersensitivity: Involvement in chronic central pain after spinal hemisection in the rat. Exper Neurol 2002; 175: 347-62.
12. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004; 25(12): 613-17.
13. Palm F, Mossner R, Chen Y, et al. Reduced thermal hyperalgesia and enhanced peripheral nerve injury after hind paw inflammation in mice lacking the serotonin-transporter. Eur J Pain 2008; 12: 790-7.
14. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009; 6: 703-12.
15. Woolf CJ. Pain: moving from symptom control toward mechanismspecific pharmacologic management. Ann Intern Med 2004; 140: 441-51.
16. Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997; 20: 404-19.
17. Perrot S. Should we switch from analgesics to the concept of Pain Modifying Analgesic Drugs (PMADs) in osteoarthritis and rheumatic chronic pain conditions? Pain 2009; 146(3): 253-60.
18. Yunus MB. The concept of central sensitivity syndromes. In: Wallace DJ, Clauw DJ, Eds. Fibromyalgia & Other Central Pain Syndromes. Philadelphia, PA: Lippincott, Williams & Wilkins. 2005; 29-44.
19. Robinson MJ, Edwards SE, Iyengar S, Bymaster F, Clark M, Katon W. Depression and pain. Front Biosci 2009; 14: 5031-51.
20. von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl 1996; 101-8.
21. Ruoff GE. Depression in the patient with chronic pain. J Fam Pract 1996; 43: S25-S33.
22. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic painassociated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13 (2): 116-37.
23. Campbell LC, Clauw DJ, Keefe FJ. Persistent pain and depression: a biopsychosocial perspective. Biol Psychiatry 2003; 54: 399-409.
24. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004; 65 (Suppl. 12): 16-9.
25. Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol 2004; 19 (Suppl. 1): S9-S13.
26. Heuser I. Anna-Monika-Prize paper. The hypothalamic-pituitaryadrenal system in depression. Pharmacopsychiatry 1998; 31: 10-13.
27. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol 2001; 13: 1009-23.
28. Blackburn-Munro G. Hypothalamic-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. Curr Pain Headache Rep 2004; 8: 116-24.
29. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 1992; 49(5): 384-7.
30. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp 1993; 172: 296-308.
31. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49(5): 391-404.
32. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005; 9(4): 463-84.
33. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-29.
34. Neugebauer V, Li W. Differential sensitization of amygdale neurons to afferent inputs in a model of arthritic pain. J Neurophysiol 2003; 89: 716-27.
35. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care 2006; 12(Suppl 9): S269-S278.
36. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ 2006; 175(3): 265-75.
37. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8: 23-33.
38. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25(6): 871-80.
39. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002; 58: 169-222.
40. Shibata M, Ohkubo T, Takahashi H, Inoki R. Modified formalin test: characteristic biphasic pain response. Pain 1989; 38: 347-52.
41. Wheeler-Aceto H, Porreca F, Cowan A. The rat paw formalin test: comparison of noxious agents. Pain 1990; 40: 229-38.
42. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17.
43. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63.
44. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77-88.
45. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 74-9.
46. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotoninnorepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004; 311: 576-84.
47. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005; 312: 726-32.
48. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-38.
49. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86: 102-6.
50. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9-21.
51. Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107(2B): 17S-26S.
52. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18(6): 350-54.
53. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
54. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67(8): 1411-20.
55. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6(5): 346-56.
56. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17(11): 1281-9.
57. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2): 160-72.
58. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996; 22(2): 285-303.
59. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50(9): 2974-84.
60. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, doubleblind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119(1-3): 5-15.
61. Russell IJ, Mease P, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial. Pain 2008; 136: 432-44.
62. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A 6-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008; 1: 91-102.
63. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: Development and validation. J heumatol 1991; 18: 728-33.
64. Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: Pooled analysis of four placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009; 11(5): 237-44.
65. von Knorring L, Perris C, Eisemann M, Eriksson U, Perris H. Pain as a symptom in depressive disorders. II. Relationship to personality traits as assessed by means of KSP. Pain 1983; 17(4): 377-84.
66. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36(4): 106-32.
67. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt CH, Demitrack MA. Duloxetine in the treatment of depression. A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-99.
68. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetinecontrolled trial. Eur Neuropsychopharmacol 2004; 14: 457-70.
69. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21: 367-78.
70. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308-15.
71. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-90.
72. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39: 43-53.
73. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007; 68: 1707-16.
74. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164 (6): 900-9.
75. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997; 72(1-2): 95-7.
76. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM. Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40(4): 337-48.
77. Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 2000; 57(6): 601-7.
78. Hoehn-Saric R. Psychic and somatic anxiety: worries, somatic symptoms and physiological changes. Acta Psychiatr Scand Suppl 1998; 393: 32-8.
79. Rickels K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001; 62 Suppl 11: 4-12.
80. Wittchen HU, Kessler RC, Bessdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl 8: 24-34.
81. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993; 153(21): 2474-80.
82. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111(1-2): 77-83.
83. Krishnan KR, France RD, Pelton S, McCann UD, Davidson J, Urban BJ. Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression. Pain 1985; 22(3): 289-94.
84. Carter CS, Maddock RJ. Chest pain in generalized anxiety disorder. Int J Psychiatry Med 1992; 22(3): 291-98.
85. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993; 150(5): 734-41.
86. Hoehn-Saric R. Generalized anxiety disorder in medical practice. Prim Psychiatry 2005; 12: 30-4.
87. Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 1998; 44(12): 1286-94.
88. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9(2): 100-7.
89. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25(3): 182-9.
90. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94(2): 149-58.
91. Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: Minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatology 2007; 34(8): 1674-83.
92. Kajdazs DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetes peripheral neuropathic pain: Evidencedbased findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Thera 2007; 29 Suppl: 2536-2546.
93. Cookson J, Gilaberte I, Desaiah D, Kajdazs DK. Treatment benefits of duloxetine in major depressive disorder as assessed by the number needed to treat. Int Clin Psychopharmacol 2006; 21: 267-73.
94. Brunton S, Wang F, Edwards SE, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010; 33(5): 393-407.